[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pre-eclampsia-complicating-pregnancy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pre-eclampsia-complicating-pregnancy":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,59,84,128],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":40,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":58},"100613200","prior-study-pre-eclampsia-risk-in-oocyte-recipients-100613200",false,"NCT07263490","PRIOR Study (Pre-eclampsia Risk In Oocyte Recipients)","PRIOR Study (Pre-eclampsia Risk In Oocyte Recipients) - Investigating Matching, Biomarkers and Outcomes.","PRIOR","Inclusion Criteria:\n\n* Age \\> 18 years\n* BMI \\\u003C 35 kg\u002Fm2\n* Normal wet smear within the past three years\n* Both nulli- and multiparous\n* Singletons and multiple gestations\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* BMI \\> 35 kg\u002Fm2\n* HIV\u002F hepatitis\n* Essential hypertension\n* Chronic kidney disease\n* Undiagnosed vaginal bleeding\n* Uterine malformations\n* Persisting ovarian cysts\n* Tumors in hypothalamus, pituitary, thyroid, or adrenal glands.\n* Previous breast cancer\n* Known BRCA 1 or 2 gene\n* Unregulated thyroid disease\n* Cardiovascular disease\n* Breast feeding\n* Present or previous chemotherapy\u002Fradiation therapy\n* Present or previous malignant disease\n* Smoking\n* Alcohol\u002Fdrug abuse","FEMALE","18 Years",{"count":20,"type":21},462,"ESTIMATED","OBSERVATIONAL","The aim of this prospective observational cohort study is to investigate the pathophysiological mechanisms behind and risk of pre-eclampsia in women pregnant after fertility treatment with oocyte donation. The participants are included in of of two cohorts. One includes women pregnant after oocyte donation whereas the other includes women pregnant after IVF treatment with autologous oocytes.\n\nParticipants will be followed throughout pregnancy with blood samples, blood pressure, clinical controls and ultrasound examinations. Clinical outcomes will be registered post-partum.",[25,26,27,28,29,30,31,32,33,34,35,36,37,38,39],"Pre-eclampsia","Oocyte Donation","Pre-Eclampsia; Complicating Pregnancy","Pre-Eclampsia; Mild","Pre-Eclampsia, Severe","Pre-eclampsia or Eclampsia With Pre-existing Hypertension","ART","Neonatal Morbidity","Neonatal Mortality","Placental Abruption","Gestational Diabetes","Preterm Labor","Post-partum Hemorrhage (PPH)","Intrauterine Growth Restriction (IUGR)","Hypertensive Disorders of Pregnancy",[25,41,31,42,43,44,45],"Preeclampsia","Gestational hypertension","Oocyte donation","Egg donation","Gamete donation","RECRUITING","2026-04-07",{"date":49,"type":50},"2026-04-13","ACTUAL",{"date":52,"type":50},"2024-10-21",{"date":54,"type":21},"2028-06-01",{"name":56,"class":57},"Copenhagen University Hospital, Hvidovre","OTHER",6,{"id":60,"slug":61,"hasResults":11,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":4,"eligibilityCriteria":65,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":66,"targetDuration":4,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":4,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":83},"100586836","remote-postpartum-blood-pressure-monitoring-and-cardiovascular-education-100586836","NCT06920563","Remote Postpartum Blood Pressure Monitoring and Cardiovascular Education","Remote Postpartum Blood Pressure Monitoring and Cardiovascular Education to Reduce Emergency Department Visits, Re-admissions and Adverse Cardiovascular Outcomes in Hypertensive Disorder of Pregnancy","Inclusion Criteria:\n\n1. Age of at least 18 years.\n2. Postpartum status.\n3. Experience new-onset hypertension during pregnancy.\n4. Enrollment in Connected MOM.\n5. Ability to provide informed consent.\n6. Establish medical care within the Ochsner System to facilitate data collection.\n\nExclusion Criteria:\n\n1. History of preeclampsia or gestational hypertension during previous pregnancy\n2. History of chronic hypertension\n3. History of coronary artery disease (myocardial infarction, coronary stent placement, coronary artery bypass grafting, spontaneous coronary artery dissection)\n4. History of ischemic CVA\n5. History of Congestive heart failure\n6. Renal dysfunction\n7. Liver dysfunction\n8. Left ventricular dysfunction\n9. Congenital heart disease\n10. Still birth at delivery",{"count":67,"type":21},296,"INTERVENTIONAL",[70],"NA","The goal of this clinical trial is to learn if patient education and regular text reminders are a feasible intervention to engage patients and reduce post partum hypertension. The main questions it aims to answer are:\n\nIs a structured postpartum remote blood pressure monitoring intervention with education and individualized medication initiation\u002Fadjustment follow-up by televisit feasible? Does a structured program reduce the occurrence of postpartum hypertension, ED visits, hospital readmissions, and adverse outcomes?\n\nParticipants will:\n\nView an educational video on HDP post-delivery Receive 1-2 times daily text messages for 6 weeks postpartum Have their blood pressure medications adjusted to lower targets post partum",[27,73],"Gestational Hypertension","2025-04-01",{"date":76,"type":50},"2025-04-09",{"date":78,"type":50},"2025-03-17",{"date":80,"type":21},"2026-10-16",{"name":82,"class":57},"Ochsner Health System",1,{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":92,"enrollmentInfo":93,"targetDuration":4,"studyType":68,"phases":95,"briefSummary":97,"conditions":98,"keywords":106,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":4},"100550855","phase-3-preeclampsia-intervention-netherlands-100550855","NCT06452498","Preeclampsia Intervention Netherlands","Metformin for the Prolongation of Pregnancy in Preterm Preeclampsia","PI-NL","Inclusion Criteria\n\nAll of the following:\n\n* Aged 18 years or older\n* Singleton pregnancy\n* Gestational age between 23+0 and 31+6 weeks\n* A diagnosis of preterm preeclampsia, defined according to modified International Society for the Study of Hypertension in Pregnancy (ISSHP) classification, including only those who have proteinuria (≥300 mg of protein in a 24-hour urine specimen or a protein-creatinine-ratio \\>50 in a single urine sample)\n* Estimated fetal weight \\>400 grams\n* No clear indication (maternal or fetal) or intention, by both the treating multidisciplinary team and the patient after counseling, to immediately deliver (or directly after corticosteroid administration) or to terminate the pregnancy otherwise.\n* Ability to understand English or Dutch\n* Ability and willingness to provide written informed consent\n\nExclusion Criteria\n\nAny of the following:\n\n* Current use of metformin or a clinical indication for the use of metformin\n* A decision for immediate delivery (including cases where corticosteroids are administered with planned delivery directly after completion of treatment) or termination of pregnancy (e.g., due to disease severity in the patient combined with a dismal prognosis for the fetus), as made by the treating multidisciplinary team and the parent(s)\n* Contraindication(s) for the use of metformin (e.g., severe renal insufficiency, acute metabolic acidosis, severe liver insufficiency)\n* Use of drugs that might interact with metformin\n* Suspicion of a major fetal anomaly and\u002For chromosomal abnormality\n* Unable or unwilling to (completely) understand or provide informed consent, due to language, culture, or other barriers","50 Years",{"count":94,"type":21},180,[96],"PHASE3","The goal of this study is to find out if pregnant individuals with preterm preeclampsia (PE) who are treated with metformin can stay pregnant for longer, and if this is safe(r) for the mother and child. Preterm PE affects about 1 in 100 pregnant individuals in the Netherlands. Signs of preterm PE can be high blood pressure and protein in the urine in the second half of pregnancy (but before 32-34 weeks of pregnancy). Other symptoms can develop, such as problems with blood clotting and how well the blood cells, liver, lungs, and brain work. The disease can lead to serious complications for both the mother and child. The only way to cure preterm PE is to make sure the child is born, and many times, children have to be delivered (very) early (before 37 weeks). Children born (very) early can suffer from infections, breathing difficulties, and problems in their development.\n\nMetformin is a medicine used to treat high blood sugar during and outside of pregnancy. In a previous study in South Africa, women with preterm PE that used metformin were able to safely remain pregnant for an extra week. Similarly, the main goal of the Preeclampsia Intervention NetherLands (PI-NL) study is to see if patients with preterm PE in the Netherlands that use metformin can remain pregnant for a longer time than patients taking a placebo. A placebo is a look-a-like capsule that contains no active ingredients. Researchers, the treating medical team, and participants will not know which participant gets which treatment. In addition, all participants will receive the standard care that all preterm PE patients get.",[99,100,27,101,30,102,103,104,105],"Pre-Eclampsia Onset Less Than 37 Weeks","Pre-Eclampsia","Pre-Eclampsia as Antepartum Condition","Pre-Eclampsia; Affecting Fetus","HELLP Syndrome Complicating Pregnancy","HELLP Syndrome","HELLP",[107,108,109,110,111,112,113,114,115,104,116,41,117],"Preterm Preeclampsia","Metformin","RCT","Placebo","Gestational Prolongation","Treatment","Pregnancy","Multicenter","Preterm","Hypertensive disorders of pregnancy","Randomized controlled trial","NOT_YET_RECRUITING","2024-06-05",{"date":121,"type":50},"2024-06-11",{"date":123,"type":21},"2024-08",{"date":125,"type":21},"2028-07",{"name":127,"class":57},"Amsterdam UMC",{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":17,"minAge":135,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":138,"conditions":139,"keywords":142,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":83},"100491444","antiphospholipid-syndrome-and-postpartum-pulmonary-artery-pressure-100491444","NCT05679206","Antiphospholipid Syndrome and Postpartum Pulmonary Artery Pressure","Association Between Preeclampsia, Antiphospholipid Syndrome and Postpartum Pulmonary Artery Pressure, Systemic Arterial Pressure and Cardiovascular Function.","Inclusion Criteria:\n\n* Age: \\> 16 years.\n* Consent or waiver of consent according Chapter 9\n* Preeclampsia\n\nDefined as:\n\n• New onset hypertension (blood pressure \\>140\u002F90mmHg on multiple occasions after 20 weeks of gestation)\n\nIn combination with new onset of 1 or more of the following:\n\n* Proteinuria (urine protein \\>300mg \u002F24h or 2+ or higher in dipstick on multiple occasions)\n* Platelet count \\\u003C100,000\u002FmicroL,\n* Serum creatinine \\>97.2 micromol\u002FL,\n* Liver transaminases at least twice the upper limit of the normal concentrations,\n* Pulmonary edema,\n* New-onset and persistent headache,\n* Visual symptoms. -Postnatal follow up at the obstetrical and cardiology clinic, Inselspital Bern, Switzerland.\n\nExclusion Criteria:\n\n* Age: \\\u003C 16 years\n* Incomplete or ambiguous data: if data confirming the eligibility criteria or data to analyze the primary endpoint is not fully available or despite efforts assessed as significantly ambiguous, the data set will be excluded from analyses, since no analysis is possible","16 Years",{"count":137,"type":21},900,"The primary goal of this observational study is to learn about postpartum pulmonary artery pressure in women who suffered from Preeclampsia and Antiphospholipid Syndrome.\n\nThe main question it aims to answer is whether the conjunction of preeclampsia with obstetric antiphospholipid syndrome significantly foster the development of long-lasting pulmonary hypertension.\n\nOnly participants who suffered from preeclampsia during pregnancy will be followed for a period up to 3 years postpartum. Researchers will compare women with or without obstetric antiphospholipid syndrome.",[27,140,141],"Antiphospholipid Syndrome in Pregnancy","Pulmonary Hypertension",[100,140,141],"2024-05-08",{"date":145,"type":50},"2024-05-09",{"date":147,"type":50},"2022-12-20",{"date":149,"type":21},"2028-12-31",{"name":151,"class":57},"Insel Gruppe AG, University Hospital Bern"]